Arrow Int’l revamps sales
This article was originally published in The Gray Sheet
Executive Summary
Following former Group Vice President-Critical Care and head of U.S. sales and marketing Philip Croxford's departure from the company, sales reps are "reporting to me directly now," said CEO Carl Anderson during a fiscal first quarter 2006 call. The firm does not plan to hire a replacement for Croxford's position. The firm brought in $113.6 mil. during the quarter, up 2% over the prior-year period, but missed its internal guidance by 1.2%-3%. The firm anticipates revenue of $117-$120 mil. for Q2. New manufacturing plants in Mexico and the Czech Republic are on track to begin catheter production this year (1"The Gray Sheet" Oct. 10, 2005, p. 13)...
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.